This Article Full Text (PDF) Services Download to citation manager

RESPONSE TO LETTER FROM CHENG ON CHOLINESTERASE INHIBITORS AND ALZHEIMER'S DISEASE OUTCOMES

Department of Internal Medicine and Clinical Gerontology University of Toulouse France

Address correspondence to Sophie Gillette-Guyonnet, PhD, Service de Médecine Interne et de Gérontologie Clinique, Pavillon J. P. Junod, Centre Hospitalier Universitaire La Grave-Casselardit, 170 avenue de Cassalardit, TSA40031, 31059 Toulouse cedex 9, France. E-mail: gillette.s{at}chu-toulouse.fr or sophie.gillette{at}free.fr

To the Editor:

As pointed out by Dr. Cheng, Alzheimer's patients often have multiple coexisting diseases and take multiple medications including some medications with cholinergic effects. In our article (1), in the bivariate analysis, both of these factors were looked at but were not significantly associated with rapid cognitive deterioration, institutionalization, and weight loss ("treatment and all variables related to dependent variable with a p value less than or equal to 0.25 after bivariate analysis and considered pertinent according to the literature were included in the model"). These factors are therefore not included in the model for the multivariate analysis.

Reference

11. Gillette-Guyonnet S, Andrieu S, Cortes F, et al. Outcome of Alzheimer's disease: potential impact of cholinesterase inhibitors. J Gerontol A Biol Sci Med Sci. 2006;61A:516-520.[Abstract/Free Full Text]

This Article Full Text (PDF) Services Download to citation manager